A placebo-controlled studyevaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder

CNS Spectrums

Volumn 14, Issue 1, 2009, Pages 41-50

  Feiger, Alan D ^a   Tourian, Karen A ^b   Rosas, Gregory R ^b   Padmanabhan, S Krishna ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLURRED VISION; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; ERYTHROCYTE COUNT; FEMALE; HEMATURIA; HUMAN; HYPERHIDROSIS; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; MYDRIASIS; NAUSEA; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; XEROSTOMIA; YAWNING; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; OUTPATIENTS; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62449126096     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900020046     Document Type: Article

References (20)

1. World Health Organization Web site. Depression. Available at: http://www.who.int/mental_health/management/depression/definition/en/print.html. Accessed August 7, 2007.
2. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on reatment decisions. J Clin Psychiatry 2007;68(suppl 8):26-34.
3. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:40-45.
4. Wyeth Pharmaceuticals. Project Listing. Neurosciences and Women's Health and Bone. Available at: http://www.wyeth.com/research/projects. Accessed May 21, 2008.
5. Pristiq [package insert]. Philadelphia, Penn: Wyeth Pharmaceuticals; 2008.
6. Boyer P, Montgomery S, Lepola U, et al. Evaluation of the efficacy and safety of fixed doses of desvenlafaxine succinate at 50 mg and 100 mg in outpatients with major depressive disorder in a placebo-controlled trial. nt Clin Psychopharmacol 2008;23:243-253.
7. Liebowitz M, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpa-tients with major depressive disorder. Curr Med Res Opin 2008;24:1877-1890.
8. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-con-trolled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677-688.
9. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian KA. A random-ized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treat-ment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-347.
10. Thase ME, Kornstein SG, Yeung PP, et al. An integrated analysis of the efficacy of desven-lafaxine succinate compared with placebo in the treatment of major depressive disorder. Poster presented at: 47th Annual NCDEU meeting. June 11-14, 2007; Boca Raton, FL.
11. Diagnostic and Statistical Manual of Mental Disorders 4th ed. Washington, DC: American Psychiatric Association; 1994.
12. Hamilton M. Hamilton Rating Scale for Depression (HAM-D). In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:526-529.
13. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Bethesda, Md: US Department of Health, Education and Welfare, National Institute of Mental Health; 1976:217-222.
14. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of ratng scales. Psychopharmacol Bull. 1982;18:69-77.
15. Raskin A. Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974;159:120-130.
16. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
17. Bech P. Psychometric developments of the Hamilton Scales: the spectrum of depression, dysthymia, and anxiety. In: Bech P, Coppen A, eds. The Hamilton Scales Berlin, Germany: Springer-Verlag; 1990:72-79.
18. The Medical Dictionary for Regulatory Activities. Available at: http://www.med-dramsso.com/MSSOWeb/index.htm. Accessed December 11, 2008.
19. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5:e45.
20. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457-494.